Table S3 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Q: What type of study is this?

This is a Quantitative Study study.

Zahra Davoudi; Thomas S. Dexheimer; Nathan P. Coussens; Thomas Silvers; Raymond G. Fox; Samantha B. Kemp; Punita Juneja; Joel Morris; Melinda G. Hollingshead; Naoko Takebe; James H. Doroshow; Beverly A. Teicher

doi:10.1158/2767-9764.30304663

October 8, 2025

Table S3 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

View Full Paper

Ask AI

Bookmark

Share

Key Points

Targeted agents combined with RAS pathway inhibitors showed noticeable activity in patient-derived spheroids.
Spheroids exhibited growth patterns similar to tumors, supporting their use in evaluating cancer therapies.
Densities from cell inoculations in 384-well microplates provide key insights into varying responses among cancer types.
Findings indicate significant implications for targeted cancer treatments in patients with KRAS mutations.

Implication

Analysis reveals activity of RAS pathway inhibitors and targeted agents in spheroids with oncogenic KRAS variants, suggesting therapeutic potential across multiple cancer types.

Abstract

Table S3. Cell inoculation densities for multicell-type tumor spheroid models per well in 384-well microplates.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Davoudi et al. (2025) studied this question.

synapsesocial.com/papers/68e861857ef2f04ca37e3bf4 https://doi.org/10.1158/2767-9764.30304663

View Full Paper

Ask AI

Bookmark

Share

Table S3 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Table S3 from RAS Pathway Inhibitors Combined with Targeted Agents Are Active in Patient-Derived Spheroids with Oncogenic KRAS Variants from Multiple Cancer Types

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading